DTx Pharma’s FALCON™ SOARS to NOVARTIS ACQUISITION
ExSight portfolio company DTx Pharma acquired by Novartis for $500 Million upfront.
Reflections from San Diego - ASCRS 2023 Round-Up
ExSight portfolio companies LensGen, Trefoil, and Elios all presented during the 2023 ASCRS Annual Meeting in San Diego.
OIS Podcast - Dompé’s Long-Term Approach
On this episode of the OIS Podcast ExSight’s co-founder, Dr. Firas Rahhal, sits down with Gianluca Rossetti, Strategic Planning & Corporate Business Development Director at Dompé. The two discuss Dompé’s storied 130-year history, keys to surviving and succeeding global challenges, views to the future, and the all-or-nothing nature of drug development.